Profile

Julie R. Park, MD

Julie R. Park, MD

Hematology-Oncology

On staff since October 1996

Children's Title: Fellowship Program Director; Thomas Bradley Armstrong Endowed Chair in Pediatric Cardiology

Academic Title: Professor of Pediatrics, UW School of Medicine; Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center

Research Center: Center for Clinical and Translational Research

Julie R. Park, MD, is attending physician at Seattle Children’s Hospital, associate professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.

Park is an active member of the Children’s Oncology Group Consortium and as chair of the COG Neuroblastoma Scientific Committee provides leadership for the development of neuroblastoma clinical research within COG.  Dr. Park’s primary research focus has been investigating novel therapies for the treatment of high-risk neuroblastoma, a rare but aggressive form of childhood cancer. She has conducted a multi-center clinical trial to determine the feasibility and toxicity of a novel induction chemotherapy regimen for high risk neuroblastoma and has collaborated with local and national investigators to optimize the use of radiation therapy as part of treatment for neuroblastoma. Dr. Park’s work has led to her development of the current national randomized phase III trial within COG for treatment of newly diagnosed high-risk neuroblastoma.. Dr. Park has ongoing collaborations with Dr. Jensen to develop adoptive immunotherapy approaches for neuroblastoma.  Dr. Park also leads the Advanced Therapeutics Program at Seattle Children’s Hospital and has steered Seattle Children’s into becoming a leading participant in the Phase I Consortium of COG and the New Approaches to Neuroblastoma Therapy Consortium. She has been actively involved in the development of novel chemotherapeutic agents that may block critical tumor cell pathways necessary for tumor cell growth and survival.

Making A Difference

Recommendations

  • Tracey Seattle, WA 06.22.14

    Dr. Park is my daughter's Doctor. Just saying those words bring hope. I know Dr. Park is absolutely invested in saving children's lives and that she works tirelessly at finding new ways to do so. We may have traveled off the beaten path, where treatment for my daughter is concerned, but only to find that Dr. Park has laid pavement. Not sure what the outcome for my child will be, but I know that Dr. Park is doing all she can to save her. Thank you Dr. Park.

  • Heather Redmond, WA 07.10.13

    Dr. Park did a wonderful job in her medical treatment of my daughter! We began the journey full of fears and worries, and we are so fortunate to have had the best possible outcome. I firmly believe that much of this is due to Dr. Park's wealth of experience, close monitoring and her willingness to listen to my concerns. I always feel that my daughter's best interests are Dr. Park's primary concern, and she has always been very compassionate and caring towards me - even when I was having a hard time coming to grips with what was happening. Anyone who has Dr. Park as their child's oncologist is very lucky to have her!

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

University of Vermont College of Medicine, Burlington

Clinical Interests

Neuroblastoma, Novel therapies, Supportive care guidelines for care of oncologic patients, Post-transplant lymphoproliferative disease

Research Description

I am an active member of the Children's Oncology Group (COG) Consortium, coordinating the center's participation in clinical trials for treatment of neuroblastoma and non-Hodgkin lymphoma. As the oncology division director of Advanced Developmental Therapeutics, I oversee participation in national NIH-funded Phase I clinical research consortia, including the COG Phase I Consortium and the New Approaches to Neuroblastoma Therapy (NANT) Consortium.

My primary research focus is to discover novel therapies for the treatment of high-risk pediatric neuroblastoma using both adoptive immunotherapy and novel molecularly targeted approaches. I am the principal investigator for a national randomized Phase III trial within COG for treatment of newly diagnosed high-risk neuroblastoma.

Research Focus Area

Cancer

Awards and Honors

Award Name Award Description Awarded By Award Date
SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
Seattle's Top Doc Seattle Met Magazine 2013
Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
U.S. News Top Doctor U.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
Benjamin Towne Endowed Chair in Neuroblastoma Benjamin Towne Foundation 2009

Publications

  • Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM
    Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
    Pediatric blood & cancer , 2013 Dec. 18
  • Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H
    Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Cancer , 2013 Oct. 15 : 119(20)3718-26
  • Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG
    Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
    The lancet oncology , 2013 Sept. : 14(10)999-1008
  • Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA
    A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
    Bone marrow transplantation , 2013 July : 48(7)947-52
  • Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M, COG Neuroblastoma Committee
    Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
    Pediatric blood & cancer , 2013 June : 60(6)985-93
  • Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK
    Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine , 2013 Apr, : 54(4)541-8
  • Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H
    Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
    Pediatric blood & cancer , 2013 Mar. : 60(3)363-70
  • Moreno L, Barone G, Park JR, Pearson AD
    About the benefits of immunotherapy for high-risk neuroblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2013 Feb. 10 : 31(5)649-50
  • Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ
    Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons , 2012 Nov. : 12(11)3069-75
  • Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR
    A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2012 Sept. 15 : 18(18)5081-9
  • Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C
    Functional genomics identifies therapeutic targets for MYC-driven cancer.
    Proceedings of the National Academy of Sciences of the United States of America , 2012 June 12 : 109(24)9545-50
  • Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X, Marr KA
    Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.
    Journal of the Pediatric Infectious Diseases Society , 2012 June : 1(2)103-111
  • Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA
    Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
    Drug metabolism and disposition: the biological fate of chemicals , 2012 Jan. : 40(1)54-63
  • Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK
    Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Nov. 20 : 29(33)4351-7
  • Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM
    Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
    Cancer chemotherapy and pharmacology , 2011 Oct. : 68(4)1057-65
  • Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG
    A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
    Pediatric blood & cancer , 2011 Aug. : 57(2)275-82
  • Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC
    Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Aug. 1 : 3623-9
  • Park JR, Eggert A, Caron H
    Neuroblastoma: biology, prognosis, and treatment.
    Hematology/oncology clinics of North America , 2010 Feb. : 65-86
  • Fong A, Park JR
    High-risk neuroblastoma: a therapy in evolution.
    Pediatric hematology and oncology , 2009 Nov. : 539-48
  • Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK
    Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Mar. 10 : 1290-6
  • McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR
    Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
    Journal of clinical pharmacology , 2009 Jan. : 88-102
  • Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK
    Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
    Pediatric blood & cancer , 2009 Jan. : 44-50
  • Tasian SK, Park JR, Martin ET, Englund JA
    Influenza-associated morbidity in children with cancer.
    Pediatric blood & cancer , 2008 May : 983-7
  • Park JR, Eggert A, Caron H
    Neuroblastoma: biology, prognosis, and treatment.
    Pediatric clinics of North America , 2008 Feb. : 97-120, x
  • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC
    Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Molecular therapy : the journal of the American Society of Gene Therapy , 2007 Apr, : 825-33
  • Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC
    Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Sept. 20 : 6481-8
  • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS
    Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
    Pediatric blood & cancer , 2004 Oct. : 571-9
  • Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI
    Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2004 Aug. 15 : 5335-41
  • Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR
    Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
    Cancer , 2004 Mar. 15 : 1268-75
  • Wright JA, Bradfield SM, Park JR, Hawkins DS
    Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
    Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Apr, : 286-91
  • Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T
    Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Medical and pediatric oncology , 2003 Feb. : 93-8

Presentations

Presentations Title Event Location Date
Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Oct. 1, 2009
Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown June 1, 2009
Accessing Novel Therapies and Navigating the Maze - The Pediatric Oncologist's Perspective American Society of Clinical Oncology, Educational Session Orlando, FL June 1, 2009
Targeting Treatment to Improve Outcomes for Childhood Cancer Circle of Care Symposium, Seattle Children’s Hospital Seattle, WA May 1, 2009
Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009
Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009

Research Funding

Grant Title Grantor Amount Award Date
Children's Oncology Group - Phase I pilot consortium formed under the Children's Oncology Group to conduct Phase I clinical research trials NIH/NCI - U01 CA097452-06 Aug. 1, 2012 - July 31, 2017
Pharmacogenetics of Cyclophosphamide ADRs in Children NIH/NCI - R21 CA162059-01 Sept. 1, 2011 - Aug. 31, 2013
NIH-U10 CA098543-05 NIH March 1, 2008 - Feb. 28, 2013
Children's Oncology Group Chair's Grant - Chair Neuroblastoma, Chair ANBL0532 NIH/NCI - U10 CA098543-05 March 1, 2008 - Feb. 28, 2013
Children's Oncology Group - Phase I Study Chair NIH/NCI - U10 CA97452-06 Aug. 1, 2007 - July 31, 2011
Translation Research for Pediatric Solid Tumors Alex’s Lemonade Stand Foundation $200,000.00 July 1, 2007
Phase I-II Safety & Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed-Refractory Solid Tumors Wyeth Pharmaceuticals Jan. 17, 2007 - Jan. 16, 2010
Genetic Predisposition to Chemotherapy Toxicity in Children Receiving Cyclophosphamide CHRMC Gift Income Genetic Predisposition to Chemotherapy Toxicity in Children Receiving Cyclophosphamide Endowment Oct. 1, 2005
Biology and Therapy of High Risk Neuroblastoma NIH/NCI - P01 CA81403-08 June 1, 2003 - May 31, 2013
Novel therapies for high-risk neuroblastoma NIH/NCI - K23 CA87058-05 July 1, 2002 - June 30, 2007
Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma 7. CHRMC Gift Income Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma Endowment Dec. 1, 1999